{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:13:18Z","timestamp":1772244798600,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Primary central nervous system lymphoma (PCNSL) is a rare B-cell lymphoma of central nervous system, which is often found in immunocompromised patients. The common clinical treatment of PCNSL is methotrexate (MTX) and whole brain radiation therapy. With the development of tumour immunology research, the tumour microenvironment of PCNSL is characterised by abnormal expression of different immune signature molecules and patients with PCNSL may benefit from tumour immunotherapy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In our research, RNA-seq data from 82 PCNSL patients were collated by mining the microarray data from the GEO database. All samples were classified into three types related to tumour immune response by the Cibersort algorithm and consistent clustering. Differential analysis of genes was used to uncover 2 sets of differential genes associated with tumour immunity. The ICI scores of each sample were obtained by PCA algorithm, and the relationship between ICI scores and immune checkpoint expression, immunotherapy and drug sensitivity was investigated. Genes associated with ICI scores and their functional characteristics were investigated by WGCNA analysis and PPI analysis, based on the ICI scores of each sample.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The tumour microenvironment in PCNSL has a greater relationship with the tumour immune response. ICI scores obtained from 375 differential genes were associated with multiple immune responses in PCNSL. PCNSL patients with higher ICI scores had a better tumour microenvironment and were sensitive to immunotherapy and some small molecule drug. This study also identified 64 genes associated with ICI scores, which may serve as important therapeutic and prognostic targets for PCNSL.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The presence of multiple immunosuppressive responses in the tumour microenvironment of PCNSL which suggested that improving the immune function of PCNSL patients through immunotherapy and targeted therapies can be an effective treatment for PCNSL. And the ICI score and associated genes may also provide a better predictor of the clinical use of immunotherapy.<\/jats:p>","DOI":"10.3389\/fgene.2022.921823","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:41:15Z","timestamp":1660711275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular characteristics of immunocytes infiltration in primary central nervous system lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Linyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingsong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqing","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Don","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/0284186X.2021.1881161","article-title":"PD-L1 and Ido1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS","volume":"60","author":"Abdulla","year":"2021","journal-title":"Acta Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.7150\/thno.54343","article-title":"The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling","volume":"11","author":"Alame","year":"2021","journal-title":"Theranostics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.hemonc.2018.02.001","article-title":"Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?","volume":"12","author":"Atilla","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.crad.2016.02.006","article-title":"Lymphomatous involvement of the central nervous system","volume":"71","author":"Bathla","year":"2016","journal-title":"Clin. Radiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/his.12706","article-title":"Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart","volume":"67","author":"Chang","year":"2015","journal-title":"Histopathology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2214\/ajr.176.5.1761319","article-title":"Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances","volume":"176","author":"Erdag","year":"2001","journal-title":"AJR. Am. J. Roentgenol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12885-020-06755-y","article-title":"PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma","volume":"20","author":"Furuse","year":"2020","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1389202916666150707155610","article-title":"miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma","volume":"16","author":"Ivo D'Urso","year":"2015","journal-title":"Curr. Genomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nov197","article-title":"Lymphomatosis cerebri: A rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature","volume":"18","author":"Izquierdo","year":"2016","journal-title":"Neuro. Oncol."},{"key":"B12","first-page":"240","article-title":"World health organization: Pathology and genetics of tumors of haematopoietic and lymphoid tissues","author":"Kluin","year":"2008","journal-title":"Prim. diffuse large B-cell lymphoma CNS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12253-019-00605-4","article-title":"miR-370 sensitizes TMZ response dependent of MGMT status in primary central nervous system lymphoma","volume":"26","author":"Li","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21147\/j.issn.1000-9604.2020.03.03","article-title":"Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives","volume":"32","author":"Lin","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1627470","article-title":"Primary central nervous system lymphoma","volume":"38","author":"L\u00f6w","year":"2018","journal-title":"Semin. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3960\/jslrt.18001","article-title":"The expression of PD-1 ligands and Ido1 by macrophage\/microglia in primary central nervous system lymphoma","volume":"58","author":"Miyasato","year":"2018","journal-title":"J. Clin. Exp. Hematop."},{"key":"B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.32598\/bcn.11.4.2542.1","article-title":"Immune checkpoint molecules in primary diffuse large B-cell lymphoma of the central nervous system","volume":"11","author":"Monabati","year":"2020","journal-title":"Basic Clin. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"vdaa018","DOI":"10.1093\/noajnl\/vdaa018","article-title":"Primary CNS lymphoma commonly expresses immune response biomarkers","volume":"2","author":"Ou","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","author":"Pentsova","year":"2014","journal-title":"J. Neurooncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.15009","article-title":"Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model","volume":"183","author":"Qiu","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00417-012-2037-1","article-title":"IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas","volume":"250","author":"Ramkumar","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"31254","DOI":"10.18632\/oncotarget.16115","article-title":"Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma","volume":"8","author":"Ruggieri","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1080\/10428194.2019.1620942","article-title":"Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma","volume":"60","author":"Sethi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.2147\/CMAR.S255482","article-title":"High level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma","volume":"12","author":"Shao","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1634\/theoncologist.2008-0236","article-title":"Primary CNS lymphoma in immunocompetent patients","volume":"14","author":"Sierra del Rio","year":"2009","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0210400","DOI":"10.1371\/journal.pone.0210400","article-title":"MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma","volume":"14","author":"Takashima","year":"2019","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0229577","DOI":"10.1371\/journal.pone.0229577","article-title":"miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma","volume":"15","author":"Takashima","year":"2020","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.1038\/s41598-019-46473-5","article-title":"Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1\/Th-2 status is guaranteed for prognosis prediction in PCNSL","volume":"9","author":"Takashima","year":"2019","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10014-020-00386-8","article-title":"Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas","volume":"38","author":"Tang","year":"2021","journal-title":"Brain Tumor Pathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3390\/cancers13123073","article-title":"Targeted therapies and immune checkpoint inhibitors in primary CNS lymphoma","volume":"13","author":"Wirsching","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.921823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:41:18Z","timestamp":1660711278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.921823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":35,"alternative-id":["10.3389\/fgene.2022.921823"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.921823","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"921823"}}